Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading Chinese pharmaceutical distribution company, has announced the resignation of Zhou Jun from his roles as chairman, non-executive director, convener, and committee member of the Strategy Committee of the Board of Directors. Zhou cites personal reasons for his departure and will not retain any positions within the company or its subsidiaries following his resignation. In a subsequent development, Zhou Jun, also the president of Shanghai Industrial Investment (Holdings) Co., Ltd, became the subject of a disciplinary review and investigation, as reported by “Lianjieshanghai,” the official WeChat account of the Shanghai Municipal Commission for Discipline Inspection of the CPC.
Previous Investigations Involving Shanghai Pharma Executives
This is not the first instance of government scrutiny involving Shanghai Pharma’s senior executives. In September 2023, Pan Deqing, vice president of SPH, resigned. Shortly thereafter, Lianjieshanghai disclosed that Pan Deqing, along with Li Ping, general manager of Shanghai Shangke, a subsidiary of SPH, Chen Binhua, general manager of SPH No.1 Biochemical & Pharmaceutical Co., Ltd., and Huang Zhenhui, former vice general manager of the same subsidiary, were suspected of serious disciplinary and legal violations and were under investigation.- Flcube.com
